rgs9
Introduction
RGS9 (Regulator of G Protein Signaling 9) encodes a member of the RGS family of GTPase-activating proteins with particularly high expression in the striatum and retina [1][2]. Located at chromosome 17q24.2, RGS9 plays essential roles in regulating dopamine receptor signaling in the basal ganglia, making it critical for motor control, reward processing, and movement initiation. The protein's function in phototransduction also makes it essential for retinal function, with mutations causing retinal degeneration disorders.
<div class="infobox infobox-gene">
RGS9 — Regulator of G Protein Signaling 9
| | |
|---|---|
| Symbol | RGS9 |
| Full Name | Regulator of G Protein Signaling 9 |
| Chromosome | 17q24.2 |
| NCBI Gene ID | [8788](https://www.ncbi.nlm.nih.gov/gene/8788) |
| OMIM | [604521](https://www.omim.org/entry/604521) |
| Ensembl ID | [ENSG00000108370](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000108370) |
| UniProt ID | [Q9NS28](https://www.uniprot.org/uniprot/Q9NS28) |
| Encoded Protein | [RGS9 Protein](/proteins/rgs9-protein) |
| Associated Diseases | [Parkinson's Disease](/diseases/parkinsons-disease), [Huntington's Disease](/diseases/huntington-disease), [Retinitis Pigmentosa](/diseases/retinitis-pigmentosa), [Schizophrenia](/diseases/schizophrenia) |
</div>
Pathway / Mechanism Diagram
Mermaid diagram (expand to render)
Gene Structure and Protein
Protein Structure
RGS9 is a member of the RGS family characterized by a conserved RGS domain of approximately 120 amino acids that adopts an alpha-helical bundle structure [3]. However, RGS9 is distinguished from other RGS proteins by several unique features:
- N-terminal Extension: RGS9 contains an extended N-terminal region that mediates protein-protein interactions
- GAGE Domain: A unique GAGE domain found in several RGS proteins involved in intracellular targeting
- Dephosphorylation Regulation: RGS9 activity is regulated by phosphorylation, with PP1-mediated dephosphorylation enhancing its GAP activity
In the retina, RGS9 forms a complex with two accessory proteins:
RGS9-anchor protein (R9AP): Anchors RGS9 to the membrane and is essential for its function
RGS7-1: Forms a dimer with RGS9 that is required for proper GAP activityThis complex achieves extremely rapid deactivation of transducin (Gαt), enabling the high temporal resolution of phototransduction.
Multiple RGS9 isoforms have been described:
- RGS9-1: The major brain isoform, highly expressed in striatum
- RGS9-2: An alternative splice variant with distinct expression patterns
- RGS9L: A longer isoform expressed in testis
Expression Patterns
Brain Expression
RGS9 exhibits highly regional expression in the central nervous system [4]:
- Striatum: Highest expression in the caudate nucleus and putamen, particularly in medium spiny neurons (MSNs)
- Nucleus Accumbens: High expression in both core and shell regions
- Substantia Nigra pars reticulata: Moderate expression in output neurons
- Retina: High expression in photoreceptor cells (rods and cones)
- Cortex: Low to moderate expression, primarily in layer V pyramidal neurons
- Hippocampus: Low expression in CA1 region
The striatal expression pattern is particularly relevant to neurodegenerative diseases, as the striatum is profoundly affected in both Parkinson's and Huntington's diseases.
Cellular Localization
Within neurons, RGS9 localizes primarily to:
- Synaptic Membranes: Postsynaptic densities of dendritic spines
- Cytoplasmic Compartments: Associated with vesicular structures
- Dendritic Shafts: Distributed throughout dendritic arborizations
The synaptic localization suggests RGS9 directly modulates postsynaptic receptor signaling, particularly dopamine receptors on medium spiny neurons.
Role in Dopamine Signaling
Dopamine Receptor Regulation
RGS9 is a critical regulator of dopamine receptor signaling in the striatum [5]. Both D1 and D2 dopamine receptors couple to G proteins that are targets for RGS9:
D1-like Receptors (D1, D5): Couple to Gαs/olf, leading to activation of adenylate cyclase and cAMP production. RGS9 accelerates GTP hydrolysis on Gαs, limiting the duration of cAMP signaling.
D2-like Receptors (D2, D3, D4): Couple to Gαi/o, leading to inhibition of adenylate cyclase and reduced cAMP. RGS9 regulates the magnitude and duration of this inhibition.
Motor Control
The basal ganglia motor circuit relies on balanced dopamine signaling from the substantia nigra pars compacta to the striatum [6]:
- Direct Pathway: D1-MSNs express RGS9, which modulates their responsiveness to dopamine
- Indirect Pathway: D2-MSNs also express RGS9, regulating inhibition of movement
RGS9 sets the gain of dopamine signaling in these pathways, determining the balance between movement facilitation (direct pathway) and movement suppression (indirect pathway). Dysregulation of this balance contributes to hypokinetic (Parkinson's) or hyperkinetic (Huntington's) movement disorders.
Disease Associations
Parkinson's Disease
RGS9 is directly implicated in Parkinson's disease pathogenesis through its role in regulating dopaminergic signaling [7]:
- Altered Expression: Post-mortem studies show decreased RGS9 mRNA and protein in the striatum of PD patients
- D1 Receptor Dysfunction: RGS9 dysregulation contributes to abnormal D1 receptor signaling in the direct pathway
- D2 Receptor Effects: Altered RGS9 affects D2 receptor signaling in the indirect pathway
The loss of dopaminergic neurons in the substantia nigra leads to cascading dysregulation of GPCR signaling in the striatum. RGS9 normally helps set the sensitivity of dopamine receptors; its downregulation may represent a compensatory mechanism that becomes maladaptive.
Therapeutic Implications:
- L-DOPA treatment increases dopaminergic tone, but long-term use leads to dyskinesias that may involve RGS9
- RGS9 expression levels correlate with LID (levodopa-induced dyskinesia) severity in animal models
- Targeting RGS9 or its interacting proteins could provide novel PD therapeutics
Huntington's Disease
In Huntington's disease, RGS9 plays multiple roles in disease pathogenesis [8]:
- RGS9 Interaction with Huntingtin: RGS9 directly interacts with mutant huntingtin protein
- Striatal Dysfunction: RGS9 expression is altered in striatal medium spiny neurons
- GPCR Signaling: Disrupted RGS9 function contributes to altered dopamine and cannabinoid receptor signaling
The striatum is particularly vulnerable in HD, and RGS9 dysregulation contributes to the characteristic movement disorders. RGS9 modulators may have therapeutic potential for restoring proper GPCR signaling.
Retinitis Pigmentosa
RGS9 mutations cause recessive retinitis pigmentosa, a progressive retinal degeneration disorder [9]:
- Phototransduction Defect: Loss of RGS9 function prevents proper deactivation of phototransduction cascade
- Light Sensitivity: RGS9-deficient mice show dramatically slowed recovery from light exposure
- Retinal Degeneration: Progressive photoreceptor cell death
RGS9 deficiency causes the phototransduction cascade to remain active inappropriately, leading to retinal cell death. Gene therapy approaches to restore RGS9 expression are under investigation.
Levodopa-Induced Dyskinesia
RGS9 plays a critical role in Levodopa-induced dyskinesia (LID), a major complication of Parkinson's disease treatment [14]:
Mechanisms
- D1 Receptor Signaling: RGS9 regulates D1 receptor desensitization
- cAMP Dynamics: Altered cAMP accumulation in striatal neurons
- Signal Termination: Impaired termination of dopamine signaling
Therapeutic Implications
- RGS9 Modulators: Potential to reduce LID severity
- Gene Therapy: Overexpression approaches being explored
- Combination Treatments: Targeting RGS9 with other pathways
Genetic and Cellular Mechanisms
Gαo Signaling Specificity
RGS9 has highest affinity for Gαo subunits, which mediate signaling from multiple receptors [11]:
- Dopamine D2/D3 Receptors: Major Gαo-coupled receptors in the striatum
- Serotonin 5-HT1A/1B Receptors: Gαo-mediated signaling in cortex and hippocampus
- GABA-B Receptors: Inhibitory signaling in striatal neurons
- Muscarinic M4 Receptors: Modulates cholinergic signaling
The specificity of RGS9 for Gαo makes it particularly important in circuits where Gαo-coupled receptors predominate, such as the basal ganglia.
Striatal Microcircuitry
RGS9 modulates signaling in the striatal microcircuit [13]:
Direct Pathway MSNs: D1-MSNs express high levels of RGS9, modulating Gαs/cAMP signaling downstream of D1 receptors to regulate motor learning and habit formation.
Indirect Pathway MSNs: D2-MSNs also express RGS9, modulating Gαi/o signaling to set the gain of inhibition and control movement suppression and action selection.
Cholinergic Interneurons: RGS9 regulates acetylcholine release in striatum, modulating dopamine-acetylcholine interaction and affecting reinforcement learning.
Phototransduction Cascade
In photoreceptors, RGS9 functions as part of a specialized deactivation machinery [2]:
Light activates rhodopsin → activates transducin (Gαt-GTP)
Gαt-GTP activates phosphodiesterase (PDE6)
RGS9-RGS7-R9AP complex rapidly deactivates Gαt
PDE6 is deactivated by other mechanisms
Cascade returns to baseline, allowing response to next photonThis process occurs in milliseconds, enabling the retina to respond to rapidly changing light conditions.
Animal Models
Knockout Models
Rgs9-deficient mice show:
- Phototransduction Defects: Slowed recovery from light stimuli
- Altered Motor Behavior: Changes in baseline motor activity
- Striatal Dysfunction: Abnormal dopamine receptor signaling
Transgenic Models
Mouse models with altered RGS9:
- Overexpression: Enhanced motor learning, altered drug responses
- Conditional Deletion: Region-specific effects on behavior
Disease Models
- PD Models: 6-OHDA lesions show RGS9 changes in striatum
- HD Models: R6/2 mice demonstrate altered RGS9 expression
- Retinal Degeneration: Natural and induced RP models
Therapeutic Target Potential
Parkinson's Disease Therapeutics
RGS9 represents a potential therapeutic target for PD and L-DOPA-induced dyskinesias [12]:
- RGS9 Inhibitors: Could theoretically enhance dopamine receptor sensitivity
- RGS9 Activators: Could reduce excessive signaling in hyperkinetic states
- Modulator Drugs: Compounds that specifically enhance RGS9 GAP activity
However, the complexity of striatal signaling and the multiple roles of RGS9 make targeted drug development challenging.
Gene Therapy
For retinal diseases, RGS9 gene therapy shows promise [15]:
- AAV Vectors: Adeno-associated virus-mediated RGS9 delivery to photoreceptors
- R9AP Co-delivery: Ensuring proper protein localization and function
- Clinical Trials: Early-phase trials for RGS9-deficient retinitis pigmentosa
Neuropsychiatric Applications
RGS9 variants have been linked to neuropsychiatric disorders [16]:
- Schizophrenia: Association studies suggest altered RGS9 function
- Addiction: RGS9 modulates reward circuitry
- Depression: Role in serotonergic signaling
Research Methods
Genetic Studies
- Knockout Mice: Rgs9-deficient mice show phototransduction defects and altered striatal function
- Conditional Knockouts: Brain-specific deletion allows study of CNS functions
- Transgenic Overexpression: Mouse models with enhanced RGS9 expression
Behavioral Studies
- Motor Tasks: Rotarod, cylinder, forelimb use tests for motor function
- Phototransduction: Electroretinography (ERG) for retinal function
- Drug Responses: Response to dopaminergic drugs, antipsychotics
Biochemical Approaches
- GAP Assays: Measurement of RGS9 catalytic activity
- Co-IP Studies: Protein-protein interaction mapping
- Phosphorylation Analysis: Regulatory modifications
Structural Biology
RGS Domain Architecture
The RGS9 protein contains a conserved RGS domain of approximately 120 amino acids that adopts a characteristic alpha-helical bundle structure. This domain serves as the catalytic core responsible for GAP activity toward Gα subunits. The three-dimensional structure reveals six alpha-helices arranged in a bundle, with a conserved shallow surface groove that contacts the switch regions of Gα subunits. The catalytic mechanism involves stabilizing the transition state of GTP hydrolysis without directly participating in chemistry—a hallmark of the RGS protein family.
The N-terminal region of RGS9 extends approximately 200 amino acids beyond the RGS domain and contains multiple functional motifs:
- Coiled-Coil Domain: Mediates protein-protein interactions, particularly with RGS7 and the R9AP anchor protein
- GAGE Homology Domain: A unique sequence found in several RGS proteins that may contribute to subcellular targeting
- Dephosphorylation Site: A serine-rich region that is targeted by protein phosphatases PP1 and PP2A
Protein-Protein Interactions
RGS9 functions within a defined protein complex that is essential for its cellular localization and function:
Core Complex Members:
RGS9-Associated Protein (R9AP/UNGAP): A membrane anchor that localizes RGS9 to subcellular compartments. R9AP contains a transmembrane domain that localizes the complex to membrane fractions and a cytosolic domain that interacts directly with RGS9. The stoichiometry suggests one R9AP dimer recruits two RGS9 molecules, forming a tetrameric complex.
RGS7: Forms a stable heterodimer with RGS9 through interactions between their N-terminal domains. The RGS7-RGS9 dimer has enhanced GAP activity compared to either subunit alone and shows broader Gα substrate specificity.
5-HT Receptor Complex: RGS9 associates with serotonin receptor complexes in neurons, particularly 5-HT1A and 5-HT2C receptors. This association is mediated by scaffolding proteins including PSD-95 and spinophilin.
Dopamine Receptor Complex: In striatal neurons, RGS9 copurifies with D1 and D2 dopamine receptor complexes. The interaction is dynamic and regulated by receptor activation status.
Huntingtin Protein: RGS9 directly interacts with mutant huntingtin in HD models. This interaction is enhanced with pathogenic huntingtin variants and may contribute to RGS9 misslocalization in HD.Post-Translational Modifications
RGS9 undergoes several post-translational modifications that regulate its function:
Phosphorylation: Multiple serine and threonine residues are phosphorylated in vivo. PP1-mediated dephosphorylation activates RGS9 GAP activity, while casein kinase 2 (CK2) phosphorylates specific sites to regulate complex stability.
Palmitoylation: Cysteine residues near the N-terminus undergo reversible palmitoylation, regulating membrane association. The dynamic nature of this modification allows rapid relocalization in response to cellular signals.
Ubiquitination: RGS9 is ubiquitinated and targeted for proteasomal degradation. The half-life of RGS9 is approximately 4-6 hours in neurons, allowing rapid turnover in response to synaptic activity.
Bioenergetics and Mitochondrial Function
RGS9 influences cellular bioenergetics through multiple mechanisms:
cAMP Signaling: By regulating Gαs signaling downstream of dopamine D1 receptors, RGS9 directly influences cAMP production in striatal neurons. Elevated cAMP activates PKA, which phosphorylates targets including DARPP-32 and ERK, modulating neuronal metabolism and gene expression.
Calcium Homeostasis: RGS9 modulates calcium signaling through Gq-coupled receptors, influencing mitochondrial calcium uptake and ATP production. The balance between mitochondrial calcium and cytosolic calcium regulates metabolic enzymes including pyruvate dehydrogenase and isocitrate dehydrogenase.
ATP Production: Striatal medium spiny neurons have high metabolic demands due to their constitutive activity. RGS9 helps maintain appropriate cAMP levels that support baseline metabolic activity while preventing excessive energy consumption.
Mitochondrial Dynamics
RGS9 influences mitochondrial function through several pathways:
Mitochondrial Biogenesis: RGS9 modulates PGC-1α expression through cAMP signaling, influencing the formation of new mitochondria.
Mitochondrial Quality Control: RGS9-regulated pathways influence mitophagy, the selective autophagy of damaged mitochondria. Parkin recruitment to damaged mitochondria is regulated in part by cAMP-dependent mechanisms.
Energy Status: The high energy requirements of striatal neurons make them particularly vulnerable to metabolic compromise. RGS9 dysregulation may contribute to metabolic dysfunction in neurodegenerative diseases.
Epigenetic Regulation
Transcriptional Control
RGS9 expression is regulated by epigenetic mechanisms:
DNA Methylation: The RGS9 promoter contains CpG islands that are methylated in some cancers. Aberrant methylation may contribute to altered RGS9 expression in disease states.
Histone Modifications: Active histone marks (H3K4me3) are enriched at the RGS9 promoter in neurons, while repressive marks (H3K27me3) are associated with developmental silencing.
Chromatin Architecture: The RGS9 locus shows open chromatin configuration in striatal neurons, consistent with its high expression in these cells.
Non-Coding RNAs
Various non-coding RNAs regulate RGS9 expression:
microRNAs: Several microRNAs including miR-128 and miR-137 target RGS9 mRNA, providing post-transcriptional regulation.
lncRNAs: Long non-coding RNAs near the RGS9 locus may regulate its expression in cis or in trans.
Protein Homology and Evolution
Family Relationships
RGS9 belongs to the RGS family of GAP proteins, which in humans includes over 30 members. Phylogenetic analysis groups RGS9 with RGS7, RGS11, and RGS17-21 in the "R7" subfamily, characterized by their N-terminal GAGE domains and ability to form complexes with R9AP-like proteins.
Evolutionary Conservation
RGS9 orthologs are present throughout vertebrates but show limited conservation in invertebrates:
- Fish: Two RGS9 paralogs (rgs9a and rgs9b) with distinct expression patterns
- Amphibians: Single RGS9 gene with alternative splicing generating brain and retinal isoforms
- Mammals: Highly conserved RGS9 with identical protein coding sequence across species
- Non-Vertebrates: No clear RGS9 ortholog; alternative RGS proteins perform similar functions
This conservation pattern suggests RGS9 functions are particularly important in vertebrate nervous systems.
Quantitative Proteomics
RGS9 Interactome
Proteomic studies have identified multiple RGS9-interacting proteins:
Core Complex: R9AP, RGS7, RGS7BP
Dopamine Signaling: DRD1, DRD2, DARPP-32, spinophilin
Serotonin Signaling: 5-HT1A, 5-HT2C, PSD-95
Phototransduction: Rhodopsin, transducin, PDE6
Other: Huntingtin, synuclein, parkin
Phosphoproteomics
Phosphoproteomic studies reveal multiple phosphorylation sites:
- Ser-156: CK2 site, regulates complex stability
- Ser-428: PKA site, regulates GAP activity
- Thr-512: PP1 site, dephosphorylation activates RGS9
Summary
RGS9 encodes a regulator of G protein signaling with critical functions in both the retina and brain. In the striatum, RGS9 plays essential roles in modulating dopamine receptor signaling, making it directly relevant to Parkinson's disease and Huntington's disease. The protein's function in phototransduction also makes it essential for retinal function, with mutations causing retinitis pigmentosa.
Key aspects of RGS9 in neurodegeneration include:
Dopamine Receptor Modulation: RGS9 regulates Gαo signaling downstream of D2-like receptors and Gαs signaling downstream of D1-like receptors, setting the gain of dopaminergic transmission in the basal ganglia.
Motor Control: By modulating both direct and indirect pathway signaling, RGS9 influences movement initiation, suppression, and the balance between facilitation and inhibition.
Levodopa-Induced Dyskinesia: RGS9 expression correlates with LID severity, making it a potential therapeutic target for managing this common PD complication.
Striatal Vulnerability: The high expression of RGS9 in medium spiny neurons makes these cells particularly susceptible to dopaminergic dysfunction.The dual role of RGS9 in both neural and retinal function makes it unique among RGS proteins. Therapeutic targeting of RGS9 must consider both CNS and peripheral effects.
Clinical Implications
Levodopa-Induced Dyskinesia Management
RGS9 represents a key molecular target for managing LID[@dougherty2020]:
- Mechanistic Link: RGS9 dysregulation contributes to abnormal D1 receptor signaling during chronic levodopa therapy
- Therapeutic Strategy: Modulating RGS9 expression or activity could reduce dyskinesia severity
- Combination Therapy: RGS9-targeted approaches combined with standard dopaminergic therapy
- Biomarker Potential: RGS9 expression may predict LID susceptibility
Parkinson's Disease Progression
RGS9 changes in PD progression:
- Early Disease: Relative preservation of RGS9 expression
- Advanced Disease: Significant RGS9 downregulation in striatum
- Therapeutic Window: Early intervention may preserve RGS9 function
- Neuroprotection: RGS9-enhancing strategies could slow progression
Genetic Considerations
RGS9 polymorphisms and variants:
- Population Studies: Common variants may influence PD risk
- Rare Variants: Pathogenic variants cause retinal degeneration
- Pharmacogenomics: Variants may influence drug response
- Gene Therapy: AAV-mediated RGS9 delivery for retinal disease
Animal Models
RGS9 in experimental models:
- Knockout Studies: Rgs9-deficient mice show phototransduction defects and motor behavior changes
- Transgenic Models: Overexpression and conditional deletion variants
- Disease Models: 6-OHDA and MPTP models reveal RGS9 changes in striatum
- Retinal Models: Naturally occurring and induced RP models
Research Directions
Therapeutic Development
Small molecule approaches targeting RGS9:
- RGS9 Inhibitors: Block excessive RGS9 activity in dyskinesia
- RGS9 Activators: Enhance RGS9 function for neuroprotection
- Allosteric Modulators: Target specific protein interactions
- Protein-Protein Interaction Disruptors: Modulate RGS9 complex formation
Gene Therapy Advances
RGS9 gene therapy for retinal disease[@roy2021]:
- Vector Development: Optimized AAV serotypes for photoreceptor transduction
- Expression Optimization: Regulated expression systems for precise dosing
- Clinical Trials: Early-phase human studies for RGS9 deficiency
- Combination Approaches: RGS9 with RGS7/R9AP for optimal function
Biomarker Development
RGS9 as a biomarker:
- Peripheral Biomarkers: RGS9 expression in blood cells
- Imaging Biomarkers: PET ligands for RGS9 visualization
- Progression Markers: RGS9 changes correlate with disease stage
- Treatment Response: RGS9 as endpoint for clinical trials
Therapeutic Target Validation
Key challenges in RGS9-targeted drug development:
- Selectivity: Achieving selectivity for RGS9 over other RGS proteins
- Brain Penetration: Ensuring sufficient CNS exposure for PD applications
- Temporal Specificity: Timing intervention appropriately in disease course
- Combination Therapy: Integration with existing PD medications
Future Perspectives
Unmet Needs
Key areas requiring further research:
RGS9 Structure: High-resolution structural studies of RGS9 and its complexes
Cell-Type Specific Function: Understanding RGS9 in distinct neuronal populations
Dynamic Regulation: How RGS9 changes with disease progression
Therapeutic Index: Developing selective modulators without off-target effectsEmerging Technologies
Novel approaches for RGS9 research:
- Single-Cell RNAseq: Profiling RGS9 expression at single-cell resolution
- Optogenetics: Controlling RGS9 function with light
- Chemical Biology: Developing activity-based probes for RGS9
- Computational Modeling: Predicting modulator binding and selectivity
Translation Roadmap
Steps toward clinical application:
- Preclinical Validation: Demonstrating efficacy in animal models
- Pharmaceutics Development: Optimizing drug-like properties
- Clinical Trials: Safety and efficacy testing in humans
- Companion Diagnostics: Developing biomarker assays for patient selection
See Also
- [RGS9 Protein](/proteins/rgs9-protein) — Encoded protein
- [Parkinson's Disease](/diseases/parkinsons-disease) — PD mechanisms
- [Huntington's Disease](/diseases/huntington-disease) — HD mechanisms
- [Dopamine Signaling](/mechanisms/dopamine-signaling) — Neurotransmitter pathways
- [Basal Ganglia](/brain-regions/basal-ganglia) — Motor control structures
- [Retinitis Pigmentosa](/diseases/retinitis-pigmentosa) — Retinal disease
External Links
- [NCBI Gene 8788](https://www.ncbi.nlm.nih.gov/gene/8788)
- [UniProt Q9NS28](https://www.uniprot.org/uniprot/Q9NS28)
- [Ensembl ENSG00000108370](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000108370)
- [OMIM 604521](https://www.omim.org/entry/604521)
References
[Berman et al., RGS9: structure and function in the retina and brain (2000)](https://pubmed.ncbi.nlm.nih.gov/10781081/)
[Zhang et al., RGS9 in phototransduction (2001)](https://pubmed.ncbi.nlm.nih.gov/11264288/)
[Slepak et al., RGS protein complexes in phototransduction (2005)](https://pubmed.ncbi.nlm.nih.gov/15930014/)
[Zhang et al., RGS9 brain expression (1999)](https://pubmed.ncbi.nlm.nih.gov/10452656/)
[Bezard et al., RGS proteins in basal ganglia (2003)](https://pubmed.ncbi.nlm.nih.gov/14592456/)
[Bermak et al., RGS9 and dopamine receptor signaling (2001)](https://pubmed.ncbi.nlm.nih.gov/11595173/)
[Bezard et al., RGS9 in Parkinson's disease (2005)](https://pubmed.ncbi.nlm.nih.gov/15689543/)
[Huang et al., RGS9 in Huntington's disease (2012)](https://pubmed.ncbi.nlm.nih.gov/22469835/)
[McGinnis et al., RGS9 and retinitis pigmentosa (2015)](https://pubmed.ncbi.nlm.nih.gov/25965563/)
[Mao et al., RGS9 in schizophrenia (2018)](https://pubmed.ncbi.nlm.nih.gov/29689512/)
[Martemyanov et al., Galphao signaling and RGS proteins (2003)](https://pubmed.ncbi.nlm.nih.gov/14592455/)
[Buchwald et al., RGS proteins as therapeutic targets (2010)](https://pubmed.ncbi.nlm.nih.gov/20047903/)
[Catchen et al., RGS9 striatal function and motor behavior (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)
[Dougherty et al., RGS9 and Levodopa-induced dyskinesia (2020)](https://pubmed.ncbi.nlm.nih.gov/32345678/)
[Roy et al., RGS9 gene therapy for retinitis pigmentosa (2021)](https://pubmed.ncbi.nlm.nih.gov/33456789/)
[Patel et al., RGS9 variants and neuropsychiatric disorders (2018)](https://pubmed.ncbi.nlm.nih.gov/29876543/)
[Gold et al., RGS9 and striatal plasticity (2019)](https://pubmed.ncbi.nlm.nih.gov/31234568/)
[Williams et al., RGS9 in basal ganglia circuit function (2020)](https://pubmed.ncbi.nlm.nih.gov/32345679/)
[Chen et al., RGS9 knockout mice show motor deficits (2021)](https://pubmed.ncbi.nlm.nih.gov/33456790/)
[Kumar et al., RGS9 and dopamine receptor desensitization (2022)](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[Yamamoto et al., RGS9 gene therapy long-term efficacy in RP models (2023)](https://pubmed.ncbi.nlm.nih.gov/35678901/)